Takeda $TAK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS67
PHASE 3 / 2-344
RECRUITING43
READOUTS ≤12 MONTHS17
READOUT SLIPPED >6 MO38%
Delay Index: of 50 active trials registered more than a year ago, 19 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Takeda on the live radar map → 📅 $TAK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Brentuximab vedotin NCT02979522 |
P1/2 | Active, not recruiting | Hodgkin Disease | 59 | 2020-05-05 (+3 mo) |
| Ponatinib NCT03589326 |
P3 | Active, not recruiting | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 245 | 2022-08-12 (+25 mo) |
| TAK-007 NCT05020015 |
P2 | Active, not recruiting | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | 27 | 2024-06-16 (-64 mo) |
| TAK-853 NCT06390995 |
P1/2 | Active, not recruiting | Ovarian Cancer; Solid Tumors | 28 | 2025-04-16 (-5 mo) |
| Brentuximab Vedotin NCT05673785 |
P2 | Active, not recruiting | Lymphoma | 52 | 2025-04-27 (-3 mo) |
| Vedolizumab NCT04738942 |
P3 | Active, not recruiting | Ulcerative Colitis; Crohn's Disease | 56 | 2025-05-30 (+8 mo) |
| Tetravalent Dengue Vaccine (TDV) NCT07047521 |
P3 | Active, not recruiting | Dengue Fever | 496 | 2026-06-29 (-2 mo) |
| TAK-279 NCT06254950 |
P2 | Active, not recruiting | Ulcerative Colitis | 213 | 2026-07-14 (-3 mo) |
| TAK-360 NCT06812078 |
P2 | Recruiting | Idiopathic Hypersomnia | 96 | 2026-11-30 (+9 mo) |
| TAK-360 NCT06952699 |
P2 | Recruiting | Narcolepsy Type 2 | 88 | 2026-11-30 (+8 mo) |
| TAK-861 NCT07363720 |
P3 | Active, not recruiting | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | 98 | 2026-12-17 |
| Maribavir NCT05319353 |
P3 | Recruiting | Cytomegalovirus (CMV) | 80 | 2027-01-18 |
| Zasocitinib (Dose A) NCT07244263 |
P2 | Active, not recruiting | Hidradenitis Suppurativa | 91 | 2027-02-05 |
| Teduglutide NCT06973304 |
P3 | Active, not recruiting | Short Bowel Syndrome | 13 | 2027-02-10 |
| TAK-279 NCT06233461 |
P2 | Recruiting | Crohn's Disease | 268 | 2027-02-17 (+5 mo) |
| TAK-755 NCT04683003 |
P3 | Active, not recruiting | Thrombotic Thrombocytopenic Purpura (TTP) | 77 | 2027-03-16 (+7 mo) |
| Zasocitinib NCT07108283 |
P2 | Active, not recruiting | Nonsegmental Vitiligo | 207 | 2027-03-26 (-7 mo) |
| TDV NCT06579755 |
P3 | Active, not recruiting | Dengue Fever | 800 | 2027-04-14 (+13 mo) |
| Zasocitinib NCT06671496 |
P3 | Active, not recruiting | Psoriatic Arthritis | 601 | 2027-05-18 |
| Zasocitinib NCT06671483 |
P3 | Active, not recruiting | Psoriatic Arthritis | 1583 | 2027-05-18 |
| Zasocitinib NCT07752108 |
P3 | Not yet recruiting | Palmoplantar Psoriasis | 40 | 2027-05-30 |
| VICTRIVA NCT06227910 |
P3 | Recruiting | Crohn's Disease | 396 | 2027-06-08 |
| Vedolizumab IV NCT04779320 |
P3 | Recruiting | Crohn's Disease (CD) | 120 | 2027-09-13 (+33 mo) |
| Vedolizumab IV NCT03221036 |
P3 | Active, not recruiting | Moderately to Severely Active Ulcerative Colitis | 392 | 2027-09-24 (+83 mo) |
| Rusfertide NCT07648030 |
P2 | Recruiting | Polycythemia Vera | 9 | 2027-10-28 |
| VONVENDI NCT07129343 |
P3 | Recruiting | Von Willebrand Disease (VWD) | 20 | 2027-11-25 |
| TAK-360 NCT07633301 |
P2 | Recruiting | Narcolepsy Type 1 | 92 | 2027-11-28 |
| CASCA NCT06798012 |
P2 | Recruiting | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 36 | 2027-12-02 |
| TAK-755 NCT07392450 |
P2 | Recruiting | Acute Ischemic Stroke | 222 | 2027-12-06 |
| TAK-861 NCT05816382 |
P2/3 | Recruiting | Narcolepsy Type 1 | 500 | 2028-02-28 (+14 mo) |
| Elritercept NCT05037760 |
P2 | Recruiting | Myelofibrosis | 135 | 2028-02-28 (+41 mo) |
| Mezagitamab NCT06722235 |
P3 | Recruiting | Immune Thrombocytopenic Purpura (ITP) | 171 | 2028-03-16 (+2 mo) |
| Zasocitinib NCT07403968 |
P2 | Recruiting | Crohn's Disease | 20 | 2028-03-30 |
| TAK-881 NCT06076642 |
P3 | Active, not recruiting | Primary Immunodeficiency Diseases (PID) | 53 | 2028-05-16 (+12 mo) |
| Vedolizumab IV NCT06100289 |
P3 | Recruiting | Ulcerative Colitis; Crohn's Disease | 70 | 2028-05-16 (+11 mo) |
| TAK-881 NCT06747351 |
P3 | Recruiting | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 59 | 2028-06-25 |
| TAK-226 NCT07319845 |
P2 | Recruiting | Myelodysplastic Syndromes | 42 | 2028-06-26 |
| Rusfertide NCT07765602 |
P2 | Not yet recruiting | Polycythemia Vera | 24 | 2028-07-01 |
| Fazirsiran Injection NCT06165341 |
P3 | Recruiting | Alpha1-Antitrypsin Deficiency | 50 | 2028-08-26 |
| TAK-330 NCT05156983 |
P3 | Recruiting | Coagulation Disorder | 440 | 2028-08-30 (+62 mo) |
| Mezagitamab NCT06963827 |
P3 | Recruiting | Kidney Disease | 347 | 2028-09-07 |
| IGI, 10% NCT06980480 |
P3 | Recruiting | Multiple Myeloma; Secondary Immunodeficiency | 183 | 2028-09-11 |
| Elritercept NCT06499285 |
P3 | Recruiting | Myelodysplastic Syndromes | 225 | 2028-09-15 (-42 mo) |
| MarsLight-11 NCT07217301 |
P3 | Recruiting | IO Resistant Squamous and Nonsquamous NSCLC | 1200 | 2028-11-01 |
| TAK-188 NCT07205718 |
P1/2 | Recruiting | Advanced or Metastatic Solid Tumors | 273 | 2028-12-26 |
| Idursulfase-IT NCT06031259 |
P2/3 | Active, not recruiting | Hunter Syndrome | 6 | 2029-01-01 (-60 mo) |
| Mezagitamab NCT07613359 |
P2 | Recruiting | Antibody-Mediated Rejection (AMR) | 36 | 2029-01-15 |
| Fazirsiran Injection NCT05677971 |
P3 | Recruiting | Alpha1-Antitrypsin Deficiency | 160 | 2029-01-17 (+35 mo) |
| ELRiSE MDS NCT07422480 |
P3 | Recruiting | Myelodysplastic Syndrome; Anemia | 300 | 2029-04-30 |
| Mezagitamab NCT06948318 |
P3 | Recruiting | Immune Thrombocytopenic Purpura (ITP) | 150 | 2029-07-29 |
| TAK-279 NCT06550076 |
P3 | Active, not recruiting | Plaque Psoriasis | 2099 | 2029-08-05 (+39 mo) |
| Vortioxetine tablets NCT07204314 |
P3 | Recruiting | Major Depressive Disorder | 180 | 2029-09-30 |
| Elritercept NCT04419649 |
P2 | Recruiting | Myelodysplastic Syndromes; Cytopenia | 210 | 2029-10-30 (+93 mo) |
| ELRISE MF NCT07623161 |
P3 | Recruiting | Myelofibrosis; Anemia | 324 | 2029-12-07 |
| Zasocitinib NCT07286058 |
P3 | Recruiting | Psoriatic Arthritis | 1182 | 2029-12-18 |
| Zasocitinib NCT06764615 |
P2 | Recruiting | Crohn's Disease; Ulcerative Colitis | 192 | 2029-12-30 |
| Vedolizumab NCT06443502 |
P3 | Recruiting | Pouchitis | 30 | 2030-01-31 (+1 mo) |
| TDV NCT06665035 |
P3 | Recruiting | Dengue Fever | 212 | 2030-03-03 |
| Vedolizumab IV NCT05837897 |
P3 | Recruiting | Crohn's Disease | 408 | 2030-03-08 |
| Vonicog Alfa NCT05582993 |
P3 | Recruiting | Von Willebrand Disease (VWD) | 24 | 2030-04-11 (+51 mo) |
| Zasocitinib NCT07871721 |
P3 | Not yet recruiting | Psoriatic Arthritis | 644 | 2030-04-18 |
| Vedolizumab SC NCT06405087 |
P3 | Recruiting | Ulcerative Colitis; Crohn's Disease | 70 | 2030-08-12 (-17 mo) |
| TAK-505 NCT07436728 |
P1/2 | Recruiting | Malignant Solid Tumors | 151 | 2030-08-18 |
| TAK-360 NCT07646678 |
P2/3 | Recruiting | Idiopathic Hypersomnia; Narcolepsy Type 1 | 500 | 2031-06-15 |
| Vedolizumab IV NCT05442567 |
P3 | Recruiting | Ulcerative Colitis; Crohn's Disease | 240 | 2033-02-07 (+36 mo) |
| Fazirsiran Injection NCT05899673 |
P3 | Active, not recruiting | Alpha1-Antitrypsin Deficiency | 200 | 2033-05-02 (+83 mo) |
| Zasocitinib NCT07250802 |
P3 | Recruiting | Plaque Psoriasis | 210 | 2034-07-03 |